Reference
·Supporting source
Telemedicine Registered Users in Thailand
~3–5M registered users across major platforms
Thailand's telemedicine sector saw a step-change in adoption during the COVID-19 pandemic (2020–2021), with platforms such as Doctor Anywhere, Mor Dika, Ooca (mental health), and hospital-affiliated apps collectively accumulating an estimated 3–5 million registered users by 2023. Growth has moderated post-pandemic as in-person consultations recovered, but the user base has been retained for chronic-disease follow-up, mental health, and prescription refill use cases. The Thai FDA and MOPH regulate telemedicine under the 2020 Telemedicine Practice Guidelines, which define eligible consultation types and data-storage requirements. NHSO began piloting virtual-care reimbursement for primary-care episodes in 2022, a structural demand driver for platform operators.
Figure in context
Thailand's telemedicine sector saw a step-change in adoption during the COVID-19 pandemic (2020–2021), with platforms such as Doctor Anywhere, Mor Dika, Ooca (mental health), and hospital-affiliated apps collectively accumulating an estimated 3–5 million registered users by 2023. Growth has moderated post-pandemic as in-person consultations recovered, but the user base has been retained for chronic-disease follow-up, mental health, and prescription refill use cases. The Thai FDA and MOPH regulate telemedicine under the 2020 Telemedicine Practice Guidelines, which define eligible consultation types and data-storage requirements. NHSO began piloting virtual-care reimbursement for primary-care episodes in 2022, a structural demand driver for platform operators.
Thailand's telemedicine sector saw a step-change in adoption during the COVID-19 pandemic (2020–2021), with platforms such as Doctor Anywhere, Mor Dika, Ooca (mental health), and hospital-affiliated apps collectively accumulating an estimated 3–5 million registered users by 2023. Growth has moderated post-pandemic as in-person consultations recovered, but the user base has been retained for chronic-disease follow-up, mental health, and prescription refill use cases. The Thai FDA and MOPH regulate telemedicine under the 2020 Telemedicine Practice Guidelines, which define eligible consultation types and data-storage requirements. NHSO began piloting virtual-care reimbursement for primary-care episodes in 2022, a structural demand driver for platform operators.
Time scope
FY2023
Source basis
Supporting source
Interpretation notes
What this tells you
Thailand's telemedicine sector saw a step-change in adoption during the COVID-19 pandemic (2020–2021), with platforms such as Doctor Anywhere, Mor Dika, Ooca (mental health), and hospital-affiliated apps collectively accumulating an estimated 3–5 million registered users by 2023. Growth has moderated post-pandemic as in-person consultations recovered, but the user base has been retained for chronic-disease follow-up, mental health, and prescription refill use cases. The Thai FDA and MOPH regulate telemedicine under the 2020 Telemedicine Practice Guidelines, which define eligible consultation types and data-storage requirements. NHSO began piloting virtual-care reimbursement for primary-care episodes in 2022, a structural demand driver for platform operators.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
NHSO Virtual-Care Reimbursement Budget
NHSO Annual Report and virtual-care pilot documentation, MOPH Digital Health Policy
BDMS Telehealth Consultation Volume
BDMS Annual Report, Hdcare platform disclosures, MOPH e-Health strategy reports
MOPH Smart Hospital Rollout Target
MOPH Digital Health Policy Framework, eHealth Thailand strategy documents, National Digital Economy and Society Commission
Doctor Anywhere Thailand Consultation Volume
Doctor Anywhere press releases and Series C investor documentation, APAC digital health analyst surveys
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.